IP Library Granted Patent US 8,580,981
Granted Patent B2
US 8,580,981 · App. 13/060,942 · Granted Nov 12, 2013

Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,580,981
App. No.
13/060,942
Granted
Nov 12, 2013
Kind
B2
Abstract

The present invention relates to a process for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate as well as novel intermediates for use in said process. (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate is particularly useful as an HIV protease inhibitor.

Claims (21)

1. A process for the preparation of darunavir of formula (A) or the ethanolate solvate thereof:

which comprises:

(i) reacting a compound of formula (1):

wherein PG represents an amino protecting group, with N-benzyl-isobutylamine, namely a compound of formula (2):

to obtain a compound of formula (3):

(ii) treating the compound of formula (3) to remove the PG protecting group to obtain a compound of formula (4):

(iii) coupling the compound of formula (4) with 1-([[(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yloxy]-carbonyl]oxy)-2,5-pyrrolidinedione of formula:

to obtain compound of formula (5):

(iv) removing the N-benzyl group from the compound of formula (5) to obtain a compound of formula (6):

(v) introducing a p-nitrophenylsulfonyl group into the compound of formula (6) to obtain a compound of formula (7):

(vi) reducing the nitro group of the compound of formula (7) to form darunavir

(vii) and thereafter recrystallizing from ethanol if the ethanolate solvate is desired.

2. A process according to claim 1 in which a compound of formula (1′) is reacted with N-benzyl-isobutylamine of formula (2) to yield a compound of formula (3′):

3. A process according to claim 1 in which the compound of formula (3) is treated by acid hydrolysis to remove the protecting group.

4. A process according to claim 1 for the preparation of a compound of formula (5) which comprises coupling the compound of formula (4) with 1-([[(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yloxy]carbonyl]oxy)-2,5-pyrrolidinedione of formula:

to obtain a compound of formula (5):

5. A process according to claim 1 in which removal of the N-benzyl group is effected by catalytic reduction of the compound of formula (5).

6. A compound of formula (3′):

7. A compound of formula (4):

8. A compound of formula (5):

9. A process according to claim 2 in which the compound of formula (3′) is treated by acid hydrolysis to remove the protecting group.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2015
From: JANSSEN R & D IRELAND
To: JANSSEN SCIENCES IRELAND UC
Reel/Frame 035496/0382 →
CHANGE OF NAME Recorded Sep 5, 2013
From: TIBOTEC PHARMACEUTICALS
To: JANSSEN R&D IRELAND
Reel/Frame 031140/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2011
From: WIGERINCK, PIET TOM BERT PAUL; SURLERAUX, DOMINIQUE LOUIS NESTOR GHISLAIN; VERSCHUEREN, WIM GASTON; DE KOCK, HERMAN AUGUSTINUS
To: TIBOTEC BVBA
Reel/Frame 025866/0542 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2011
From: AELTERMAN, WIM ALBERT ALEX
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 025866/0608 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2011
From: JANSSEN PHARMACEUTICA NV
To: TIBOTEC PHARMACEUTICALS
Reel/Frame 025866/0687 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2011
From: TIBOTEC BVBA
To: TIBOTEC PHARMACEUTICALS
Reel/Frame 025866/0744 →